Fifty cats with feline leukemia virus (FeLV) infection and leukemia-lymphoma complex were treated by ex vivo immunoadsorption with Staphylococcus protein A-bound filters. Most cats responded to therapy. Twelve showed tumor regression, including disappearance of tumor cells, but died later of other complications. Three have had long-term remission of more than 1 year and remain healthy. A consistent finding in these three cats was the appearance during treatment of a complement-dependent cytotoxic antibody against cat lymphoma cells (FL-74). The cytotoxic antibody increased substantially during treatment. Appearance and increase of the cytotoxic antibody was associated with disappearance of FeLV from blood and remission of leukemia. By electroblot analysis, antibody to FeLV protein (Mr, 70,000) was detected in serum prior to detection of the cytotoxic antibody. The cytotoxic antibody was found by immunofluorescence to be specific for antigens on membranes of viable FL-74 cells. By using monoclonal antibodies to FL-74 cells and to components of FeLV, the cytotoxic antibody was shown to be directed against gp70, a glycoprotein of Mr 70,000, but not against p27 of FeLV or other membrane antigen(s) of FL-74 cells. The development of a high concentration of cytotoxic antibody to FeLV gp7O may play an important role in tumor regression and in disappearance of FeLV infection.
Ex vivo immunoadsorption by Staphylococcus protein A (SPA) for treatment of cancer has aroused interest because tumor regression and immunostimulation have been observed by several investigators (1) (2) (3) (4) . Feline leukemia virus (FeLV)-induced neoplasms (e.g., lymphosarcoma or leukemia) offer excellent models for the study of these phenomena. Tumor regression has been produced in a significant number of cats treated in our laboratory by ex vivo immunoadsorption using SPA over the last 4 years (5-7). Similar tumor regression had been observed previously (8) in cats treated with a combination of whole-body irradiation and ex vivo immunoadsorption using whole Staphylococcus aureus.
Previously, we demonstrated that decrease of circulating immune complexes and correction of hypocomplementemia occurred in some treated cats (9) . Herein we show that a complement-dependent cytotoxic antibody to FL-74 cells, a feline lymphoblastoid cell line (10) , was regularly demonstrable in sera of cats that experienced dramatic clinical and hematological remission and became free of virus infection. Lactate dehydrogenase (LDHase) release (11) and vital dye exclusion were used in parallel to establish the cytotoxicity of the antibody. Absorption experiments with intact virus indicate that the cytotoxic antibody was directed against a viral envelope protein expressed on the membrane of virusinfected FL-74 cells. With monoclonal antibodies (MAbs) to FeLV as well as to FL-74 (12) cells, we show that the complement-dependent cytotoxic antibody was specific for the envelope glycoprotein (gp7O) of FeLV.
MATERIAL AND METHODS Animals. Pet cats referred to the College of Veterinary Medicine, Oklahoma State University, were selected for treatment by ex vivo immunoadsorption (5) twice a week for 10 weeks after cytologic and/or radiographic examination revealed hematopoietic neoplasia (leukemia or lymphosarcoma). Viral status of the cats was determined as described (5 The rest of the procedure followed that described under Cytotoxicity Assay for Antibodies to FL-74 Cells.
Electroblot Analysis of Antibodies to FeLV Antigens in Cat Plasma During SPA Treatment. Polyacrylamide gel electrophoresis. Purified FeLV proteins were electrophoresed in 10% acrylamide slab gels by using the discontinuous NaDodSO4 buffer system described by Laemmli (13) with phosphorylase b, bovine serum albumin, ovalbumin, carbonic anhydrase, soybean trypsin inhibitor, and y-lactalbumin (Pharmacia) ,s standards.
Elecrophporetic transfer. Viral proteins separated by NaDodSO4 slab gel electrophoresis were transferred to nitrocellulose paper as described by Towbin et al. (14) . (buffer T) for 1 hr at 370C. The blots were then rinsed five times with buffer T and incubated for 2 hr at room temperature with normal cat serum or serum from leukemic cats undergoing SPA treatment at a 1:20 dilution in 3% bovine serum albumin in buffer T. Goat anti-FeLV gp7O antiserum (National Institutes of Health) was used to identify gp7O in the blot. The nitrocellulose strips were washed with five changes of buffer T and incubated with horseradish peroxidase-conjugated rabbit anti-cat IgG or rabbit anti-goat IgG antibodies (Cappel Laboratories, Cochranville, PA) at a dilution of 1:400 for 2 hr at room temperature. The blots were once again washed five times in buffer T and soaked in a solution containing 0.5 mg of 4-chloro-1-naphthol (Sigma) per ml, 0.01% H202, and 0.05 M Tris HCl (pH 7.4). Color development was stopped by washing with deionized water. (Fig. 1) By electroblot analysis of the serum of cat 109, antibody to FeLV protein (Mr, 70,000) and to a FeLV protein of Mr 60,000 first appeared during week 5 of treatment (Fig. 3, lane  5) . Antibody to the core protein p27 (lane 12) and to other unidentified viral proteins appeared later during weeks 9 through 12. Marker protein gp7O is in lane 13. Whether this antibody to Mr 70,000 protein (lanes 5-12) is the same as the cytotoxic antibody present in the cat's serum is unknown.
RESULTS

Detection of Cytotoxic
Virus reappeared in the blood of cat 101 4.5 months after cessation of treatment, and the cytotoxic antibody first decreased and then disappeared from the circulation.
Absorption Assays. Absorption studies of the cytotoxic antibody in the plasma of cat 101 with FeLV or MMTV show that, although 30 ,ul of FeLV failed to absorb the cytotoxic activity, 50 ,ul of FeLV reduced the cytotoxicity by =74% (Table 4) . No reduction in cytotoxic activity occurred in the plasma after absorption with MMTV. Similar findings were observed with sera of the other two cats with circulating cytotoxic antibody.
Inhibition of Cytotoxic Activity in Cat Plasma Against FL-74 Cells with MAbs to FeLV and FL-74 Cells. Incubation in the presence of complement of FL-74 cells with cat 101 plasma obtained between the 16th and 20th treatment resulted in -69-90% cell death, depending on the concentration of the cytotoxic antibody in the plasma sample (Table 5) . When the target cells were allowed to react prior to the addition of the cytotoxic antibody with various dilutions of ascites fluid containing the MAb 73.5 that was reactive with FeLV gp7O, complement-mediated lysis was almost completely abolished. MAbs 7.2 and 6.5 failed to abolish cytotoxic activity against FL-74 cells in the plasma samples. The relative inability of each of these three MAbs to mediate complementdependent lysis of FL-74 cells on their own was shown in separate studies. When FL-74 cells were incubated with ascites fluid (at dilutions 1:10, 1:50, and 1:100) containing the respective MAbs (7.2, 73.5 and 6.5), followed by incubation with fresh GPS as a source of complement, the percentage of cell death was found to be 6-18% by trypan blue exclusion. No difference in the percentage of cell death was observed when fresh GPS was replaced by heat-inactivated (56°C for 30 min) GPS. These results indicate that the cytotoxic antibody developed against cat lymphoma cell (FL-74) is direct- 
Cytotoxic antibody (Ab) was determined as in In all three cats studied in detail that went into complete long-lasting remission, the cytotoxic antibody for FL-74 cells appeared in the circulation. Further, evidence of viremia disappeared while this antibody was present in high concentration in the circulation. When the cytotoxic antibody dropped to an undetectable level 4 months after remission in one cat, viremia reappeared. Nonetheless, this cat has remained in complete hematologic and clinical remision for more than 1 year. Two other cats have retained cytotoxic antibody and are still negative for both virus and leukemialymphoma. These findings suggest that antibody directed toward the gp7O antigen was cytotoxic to the tumor cells and either lytic to or neutralizing for the virus. Electroblot analysis of serial samples from a treated cat that became virusnegative showed that an antibody to a Mr 70,000 protein was demonstrable in the serum before the complement-dependent cytotoxic antibody. Whether the antibody detected by electroblot is the same as the cytotoxic antibody needs to be established.
These studies associating cytotoxic antibodies with virus disappearance and tumor regression do not of course establish that the mechanism of tumor regression is solely due to the antibody. Other influences may be equally or more important.
The relationship of the cytotoxic antibody we are studying to the antibody against feline oncornavirus-associated cell membrane antigen § discovered by Essex and co-workers that has been much discussed by Hardy, Essex, and coworkers (15-17) must be mentioned. Our evidence is not conclusive on this point, but the absorption studies with virus indicate that our cytotoxic antibody is directed against an antigen on the intact virus as well as on the FL-74 cells. Vedbrat el al. (18) showed that viremic cat sera reactive with FL-74 cells as determined by IFA also react with FeLV proteins in contrast to prior reports (19) (20) (21) . Using immunoelectron microscopy, they demonstrated that feline oncornavirus-associated cell membrane antigen activity is due to FeLV gp7O epitopes expressed on the surface of cat lymphoma cells and FeLV group C-infected cells. Their finding would be consonant with our observation that the cytotoxic antibody associated with complete long-lasting remission in our cats showed specificity both for virus-infected FL-74 cells and for gp7O of the virus itself. §Feline oncornavirus-associated cell membrane membrane antigen (FOCMA) was first described by Essex and his co-workers as an antigen detected by immunofluorescence antibody reaction of certain cat sera with the surface of FL-74 cells.
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